SCHEMBL3532387

SCHEMBL3532387

COc1cc(S)ccc1OCC(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
HDAC1 Q13547 2/20 0.53
HDAC2 Q92769 2/20 0.53
HDAC8 Q9BY41 2/20 0.53
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
APP P05067 2/20 0.51
GLA P06280 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TSHR P16473 1/20 0.47
MPO P05164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3271558 0.85 APP (0.53) POLBSMN1; SMN2MEN1KMT2AAPP
SCHEMBL5275178 0.81 POLB (0.64) POLBSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL25747602 0.81 POLB (0.64) POLBSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL25685569 0.81 POLB (0.64) POLBSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL2823002 0.81 PPARD (0.52) POLBSMN1; SMN2GLAL3MBTL1TSHR
SCHEMBL4009680 0.80 PTGDR2 (0.65) POLBSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL9774170 0.80 KMT2A (0.75) POLBSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL1531321 0.80 POLB (0.62) POLBSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL3268767 0.80 PTGDR2 (0.50) POLBSMN1; SMN2MEN1KMT2AGLA
SCHEMBL1332214 0.80 TDP1 (0.68) POLBSMN1; SMN2MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816385-B2 Dimeric dicarboxylic acid derivatives, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-10-19 US disclosed
EP-1578716-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2005-09-28 EP disclosed
US-20040259950-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2004-12-23 US disclosed
WO-2004056740-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259950-A1 Novel compounds, their preparation and use PPARG, PPARA, PPARD POLB 1313/4885SMN1; SMN2 4505/4885MEN1 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.